Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing.
In breast cancer especially, only a small number of patients are even eligible to undergo treatment with immunotherapies, and most see little benefit.
But in a pre-clinical study led by the Duke Cancer Institute, researchers outlined a potential way to improve those results by uncloaking breast cancer tumours to the body's immune system.
Publishing this month in the journal Nature Communications, the researchers identified an enzyme in cells involved in regulating the growth and spread of breast cancers.
Testing in mice, they demonstrated a way to shut down the enzyme's activity to allow T-cells to mount an immune attack.
"We found that inhibition of the activity of this enzyme decreased the ability of macrophages in tumours to suppress an immune attack on cancer cells and indeed encouraged them to start producing chemicals that attract more cancer-killing T cells into the tumour," said Donald McDonnell, Ph.D., chair of Duke's Department of Pharmacology & Cancer Biology.
"We can basically uncloak the tumour to the immune system," McDonnell said.
McDonnell and colleagues, including lead author and collaborator Luigi Racioppi, M.D., Ph.D., reported that a kinase, or enzyme, called CaMKK2 is highly expressed in macrophages within human breast tumours.
They performed a series of exploratory studies that revealed the molecule's potential utility as a therapeutic target for breast cancer.
Working with colleagues at the University of North Carolina at Chapel Hill, they developed a new class of drugs that inhibited the growth of human breast tumours grown in mice.
"The use of this molecule suppressed tumour growth not only by increasing the accumulation of tumour-killing T cells, but also by reducing the tumour's capability to suppress T cell activity," said McDonnell.
"It's solving two problems, like we couldn't get into the bar, and if we did, we couldn't get a drink. Now we can do both," McDonnell explained.
McDonnell said additional studies are ongoing, with the goal of acquiring data to launch a clinical trial in breast cancer patients within the next 18 months.
Source: Duke University Medical Center